Remember when Bollywood heroes cured diseases in one song sequence? Ipca’s management is trying the same — but with APIs, generics, and cardiovascular divisions. Domestic business grew, exports flexed, and Unichem… well, coughed a little. The call had everything — margins drama, Euro penalties, and 400 new MRs entering like extras in a Karan Johar wedding scene. Stick around, because the punchline is: “profits are up, but subsidiaries are still on ventilator support.”
2. At a Glance
Revenue up 12% – Growth engine still alive; not just placebo effect.
Standalone Net Profit up 26% – Doctors call this a healthy pulse.
Consolidated Net Profit up 18% – Slightly less, thanks to Unichem catching a cold.
Standalone Margins 23.8% vs 22.2% – A little steroid boost.
Consolidated EBITDA margin 18.4% vs 18.5% – Flatlined, blame Unichem & Euro penalties.
API business up 12% – New molecules, same addiction.
Stock? Likely sipping antibiotics, waiting for guidance clarity.
3. Management’s Key Commentary
Quote: “Domestic business grew ~10%. Six brands still in top 30.” (Translation: We’re the Salman Khan of generics — not top 5, but always on screen.)
Quote: “Export branded formulations up 10%, generics up 15%.” (Translation: NRIs still love us more than local patients.)
Quote: “Standalone margins rose 160 bps to 23.8%.” (Translation: Product mix worked; we sold the profitable pills, not the headache ones.)
Quote: “Unichem margins down due to Asia/Brazil declines & Euro provisions.” (Translation: Unichem is that cousin who eats all the biryani but brings no mithai.)
Quote: “Cardiovascular therapy was weak due to reorganization.” (Translation: We added 400 MRs and shuffled divisions — classic HR experiment gone wrong.)
Quote: “UK market was bad — products sold below cost.” (Translation: Welcome to London Bazaar Discount Sale: ‘Buy paracetamol, get depression free’.)
Quote: “Subsidiaries like Onyx slipped after 10 years of profits.” (Translation: Even side-hustles can hit midlife crisis.)
4. Numbers Decoded
Source table
Metric
Value Q1 FY26
YoY Change
One-Line Analysis
Revenue – The Hero
₹124 cr (branded exports), ₹326 cr (generics)
+10–15%
Exports carried the day, locals less generous.
API – The Workhorse
₹?? (not disclosed fully)
+12%
APIs still pay rent, stable and steady.
Standalone Margin
23.82%
+160 bps
Magic of product mix, nothing revolutionary.
Consol EBITDA Margin
18.39%
-13 bps
Unichem dragged the average down.
Standalone Net Profit
₹262 cr
+26%
Doctor-approved growth shot.
Consolidated Net Profit
₹234 cr
+18%
Still healthy, but subsidiaries sneezed.
(Ipca’s balance sheet is fine, but Unichem looks like it skipped its antibiotics mid-course.)
5. Analyst Questions
Nomura: Why margins down at Unichem? (Mgmt: Myanmar import license drama, Brazil cough, Euro penalty.
